Please enable JavaScript to continue using this application.

Compare $ICCC vs $RLYB | Chartloom

Compare

$ICCC vs $RLYB

ImmuCell Corp · Rallybio Corp

ICCC

ImmuCell Corp

RLYB

Rallybio Corp

Compare $ICCC vs $RLYB

Comparing ImmuCell Corp and Rallybio Corp

ICCCImmuCell Corp

RLYBRallybio Corp

ICCCImmuCell Corp

Market cap

$89M

P/E (TTM)

114.37x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

8.5%

YTD performance

65.5%

52W performance

48.7%

FCF yield

4.8%

RLYBRallybio Corp

Market cap

$90M

P/E (TTM)

2.17x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-15.1%

YTD performance

200.8%

52W performance

269.6%

FCF yield

29.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ICCC

RLYB

Detailed metrics comparison

ICCC

ImmuCell Corp

RLYB

Rallybio Corp

Market Cap

ICCC$89M

RLYB$90M

Enterprise Value

ICCC$88M

RLYB$-3M

Price

ICCC$9.80

RLYB$17.02

P/E Ratio

ICCC114.37x

RLYB2.17x

P/S Ratio

ICCC2.89x

RLYB139.64x

EV/Sales

ICCC2.87x

RLYB-4.09x

EV/EBITDA

ICCC14.10x

RLYB-0.10x

P/B Ratio

ICCC2.82x

RLYB0.96x

P/FCF Ratio

ICCC21.04x

RLYB3.38x

EV/FCF

ICCC20.91x

RLYB-0.10x

PEG Ratio

ICCCN/A

RLYBN/A

Forward P/E (NTM)

ICCCN/A

RLYBN/A

Forward P/S (NTM)

ICCCN/A

RLYBN/A

Revenue (TTM)

ICCC$31M

RLYB$646K

Revenue Growth (YoY)

ICCC8.5%

RLYB-15.1%

Forward Rev Growth

ICCC0.0%

RLYB499.1%

Gross Margin (TTM)

ICCC40.3%

RLYB0.0%

Operating Margin (TTM)

ICCC3.9%

RLYB0.0%

EBITDA Margin (TTM)

ICCC20.4%

RLYB-4284.8%

Net Margin (TTM)

ICCC2.6%

RLYB7051.2%

FCF Margin (TTM)

ICCC13.7%

RLYB4135.0%

Net Income (TTM)

ICCC$787K

RLYB$46M

FCF (TTM)

ICCC$4M

RLYB$27M

EPS (TTM)

ICCC$0.09

RLYB$7.86

ROE (TTM)

ICCC2.7%

RLYB68.6%

ROA (TTM)

ICCC1.8%

RLYB64.5%

ROIC (TTM)

ICCC2.1%

RLYB68.6%

Cash

ICCC$9M

RLYB$93M

Debt

ICCC$8M

RLYB$0

Net Cash/Debt

ICCC$557K

RLYB$93M

Current Ratio (TTM)

ICCC4.75x

RLYB27.26x

Quick Ratio (TTM)

ICCC2.65x

RLYB27.01x

Debt/Equity (TTM)

ICCC0.26x

RLYB0.00x

Debt/Assets (TTM)

ICCC0.0%

RLYB0.0%

Interest Coverage (TTM)

ICCCN/A

RLYBN/A

Net Debt/EBITDA (TTM)

ICCC0.00x

RLYB0.00x

Beta

ICCC0.60

RLYB-0.75

52W Performance

ICCC48.7%

RLYB269.6%

YTD Performance

ICCC65.5%

RLYB200.8%

% from 52W High

ICCC-19.0%

RLYB-3.2%

% from 52W Low

ICCC116.8%

RLYB363.7%

Asset Turnover (TTM)

ICCC0.69x

RLYB0.01x

FCF Yield (TTM)

ICCC4.8%

RLYB29.6%

Earnings Yield (TTM)

ICCC0.9%

RLYB50.5%

Dividend Yield (TTM)

ICCCN/A

RLYBN/A

Rule of 40

ICCC22.2

RLYB4,119.9

EV/GP/RG

ICCCN/A

RLYBN/A

Ticker research

View ICCC research View RLYB research

Metric	ICCC ImmuCell Corp	RLYB Rallybio Corp
Market & Valuation
Market Cap	$89M	$90M
Enterprise Value	$88M	$-3M
Price	$9.80	$17.02
P/E Ratio	114.37x	2.17x
P/S Ratio	2.89x	139.64x
EV/Sales	2.87x	-4.09x
EV/EBITDA	14.10x	-0.10x
P/B Ratio	2.82x	0.96x
P/FCF Ratio	21.04x	3.38x
EV/FCF	20.91x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$31M	$646K
Revenue Growth (YoY)	8.5%	-15.1%
Forward Rev Growth	0.0%	499.1%
Profitability
Gross Margin (TTM)	40.3%	0.0%
Operating Margin (TTM)	3.9%	0.0%
EBITDA Margin (TTM)	20.4%	-4284.8%
Net Margin (TTM)	2.6%	7051.2%
FCF Margin (TTM)	13.7%	4135.0%
Net Income (TTM)	$787K	$46M
FCF (TTM)	$4M	$27M
EPS (TTM)	$0.09	$7.86
ROE (TTM)	2.7%	68.6%
ROA (TTM)	1.8%	64.5%
ROIC (TTM)	2.1%	68.6%
Financial Health
Cash	$9M	$93M
Debt	$8M	$0
Net Cash/Debt	$557K	$93M
Current Ratio (TTM)	4.75x	27.26x
Quick Ratio (TTM)	2.65x	27.01x
Debt/Equity (TTM)	0.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.60	-0.75
52W Performance	48.7%	269.6%
YTD Performance	65.5%	200.8%
% from 52W High	-19.0%	-3.2%
% from 52W Low	116.8%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.69x	0.01x
FCF Yield (TTM)	4.8%	29.6%
Earnings Yield (TTM)	0.9%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22.2	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View ICCC research	View RLYB research

Valuation

P/E Ratio

RLYB

2.17x

ICCC

114.37x

P/S Ratio

ICCC

2.89x

RLYB

139.64x

EV/FCF

RLYB

-0.10x

ICCC

20.91x

Growth & revenue

Revenue Growth TTM

ICCC

8.5%

RLYB

-15.1%

Forward Revenue Growth

RLYB

499.1%

ICCC

0.0%

Profitability & performance

Gross Margin

ICCC

40.3%

RLYB

0.0%

ROE

RLYB

68.6%

ICCC

2.7%

FCF Yield %

RLYB

29.6%

ICCC

4.8%

52-Week Performance

RLYB

269.6%

ICCC

48.7%

Detailed metrics comparison

ICCC

ImmuCell Corp

RLYB

Rallybio Corp

Market Cap

ICCC$89M

RLYB$90M

Enterprise Value

ICCC$88M

RLYB$-3M

Price

ICCC$9.80

RLYB$17.02

P/E Ratio

ICCC114.37x

RLYB2.17x

P/S Ratio

ICCC2.89x

RLYB139.64x

EV/Sales

ICCC2.87x

RLYB-4.09x

EV/EBITDA

ICCC14.10x

RLYB-0.10x

P/B Ratio

ICCC2.82x

RLYB0.96x

P/FCF Ratio

ICCC21.04x

RLYB3.38x

EV/FCF

ICCC20.91x

RLYB-0.10x

PEG Ratio

ICCCN/A

RLYBN/A

Forward P/E (NTM)

ICCCN/A

RLYBN/A

Forward P/S (NTM)

ICCCN/A

RLYBN/A

Revenue (TTM)

ICCC$31M

RLYB$646K

Revenue Growth (YoY)

ICCC8.5%

RLYB-15.1%

Forward Rev Growth

ICCC0.0%

RLYB499.1%

Gross Margin (TTM)

ICCC40.3%

RLYB0.0%

Operating Margin (TTM)

ICCC3.9%

RLYB0.0%

EBITDA Margin (TTM)

ICCC20.4%

RLYB-4284.8%

Net Margin (TTM)

ICCC2.6%

RLYB7051.2%

FCF Margin (TTM)

ICCC13.7%

RLYB4135.0%

Net Income (TTM)

ICCC$787K

RLYB$46M

FCF (TTM)

ICCC$4M

RLYB$27M

EPS (TTM)

ICCC$0.09

RLYB$7.86

ROE (TTM)

ICCC2.7%

RLYB68.6%

ROA (TTM)

ICCC1.8%

RLYB64.5%

ROIC (TTM)

ICCC2.1%

RLYB68.6%

Cash

ICCC$9M

RLYB$93M

Debt

ICCC$8M

RLYB$0

Net Cash/Debt

ICCC$557K

RLYB$93M

Current Ratio (TTM)

ICCC4.75x

RLYB27.26x

Quick Ratio (TTM)

ICCC2.65x

RLYB27.01x

Debt/Equity (TTM)

ICCC0.26x

RLYB0.00x

Debt/Assets (TTM)

ICCC0.0%

RLYB0.0%

Interest Coverage (TTM)

ICCCN/A

RLYBN/A

Net Debt/EBITDA (TTM)

ICCC0.00x

RLYB0.00x

Beta

ICCC0.60

RLYB-0.75

52W Performance

ICCC48.7%

RLYB269.6%

YTD Performance

ICCC65.5%

RLYB200.8%

% from 52W High

ICCC-19.0%

RLYB-3.2%

% from 52W Low

ICCC116.8%

RLYB363.7%

Asset Turnover (TTM)

ICCC0.69x

RLYB0.01x

FCF Yield (TTM)

ICCC4.8%

RLYB29.6%

Earnings Yield (TTM)

ICCC0.9%

RLYB50.5%

Dividend Yield (TTM)

ICCCN/A

RLYBN/A

Rule of 40

ICCC22.2

RLYB4,119.9

EV/GP/RG

ICCCN/A

RLYBN/A

Ticker research

View ICCC research View RLYB research

Metric	ICCC ImmuCell Corp	RLYB Rallybio Corp
Market & Valuation
Market Cap	$89M	$90M
Enterprise Value	$88M	$-3M
Price	$9.80	$17.02
P/E Ratio	114.37x	2.17x
P/S Ratio	2.89x	139.64x
EV/Sales	2.87x	-4.09x
EV/EBITDA	14.10x	-0.10x
P/B Ratio	2.82x	0.96x
P/FCF Ratio	21.04x	3.38x
EV/FCF	20.91x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$31M	$646K
Revenue Growth (YoY)	8.5%	-15.1%
Forward Rev Growth	0.0%	499.1%
Profitability
Gross Margin (TTM)	40.3%	0.0%
Operating Margin (TTM)	3.9%	0.0%
EBITDA Margin (TTM)	20.4%	-4284.8%
Net Margin (TTM)	2.6%	7051.2%
FCF Margin (TTM)	13.7%	4135.0%
Net Income (TTM)	$787K	$46M
FCF (TTM)	$4M	$27M
EPS (TTM)	$0.09	$7.86
ROE (TTM)	2.7%	68.6%
ROA (TTM)	1.8%	64.5%
ROIC (TTM)	2.1%	68.6%
Financial Health
Cash	$9M	$93M
Debt	$8M	$0
Net Cash/Debt	$557K	$93M
Current Ratio (TTM)	4.75x	27.26x
Quick Ratio (TTM)	2.65x	27.01x
Debt/Equity (TTM)	0.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.60	-0.75
52W Performance	48.7%	269.6%
YTD Performance	65.5%	200.8%
% from 52W High	-19.0%	-3.2%
% from 52W Low	116.8%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.69x	0.01x
FCF Yield (TTM)	4.8%	29.6%
Earnings Yield (TTM)	0.9%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22.2	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View ICCC research	View RLYB research